Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex 250 mg vs Nolvadex 20 mg in postmenopausal women with advanced breast cancer
jRCT2080220407Phase 3
- Sponsor
- AstraZeneca
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fulvestrant in breast cancer (2 arms), sponsored by AstraZeneca.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080220407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220407.